BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Drug Interaction Statin

Phase 1

Completed

Conditions: Acute Coronary Syndromes

Interventions: Drug: BMS-919373
Drug: Rosuvastatin
Drug: Atorvastatin

First Posted Date: 2014-03-17

Last Posted Date: 2014-08-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 26

Registration Number: NCT02089061

Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: BMS-791325
Drug: Placebo matching BMS-791325
Drug: Moxifloxacin

First Posted Date: 2014-03-12

Last Posted Date: 2014-07-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 59

Registration Number: NCT02084953

Locations: 🇺🇸
Ppd Development, Llc, Austin, Texas, United States

Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects

Phase 1

Terminated

Conditions: Healthy Adult Volunteers

Interventions: Drug: BMS-986090
Drug: Placebo matching with BMS-986090
Drug: Keyhole limpet hemocyanin

First Posted Date: 2014-03-05

Last Posted Date: 2016-05-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 130

Registration Number: NCT02079480

Locations: 🇺🇸
Parexel Baltimore Early Phase Clinical Unit, Baltimore, Maryland, United States
🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States

A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects

Phase 1

Completed

Conditions: Anticoagulation

Interventions: Drug: Apixaban
Drug: Beriplex P/N (4-Factor PCC)
Drug: Placebo (Saline solution)
Drug: Cofact (4-Factor PCC)

First Posted Date: 2014-02-28

Last Posted Date: 2015-08-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 43

Registration Number: NCT02074358

Absorption, Distribution, Metabolism and Excretion (ADME) Study of BMS-986020

Phase 1

Completed

Conditions: Immunosuppression For Disease

Interventions: Drug: [14C] BMS-986020

First Posted Date: 2014-02-20

Last Posted Date: 2014-06-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 6

Registration Number: NCT02068053

A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen

Phase 3

Completed

Conditions: Non Small Cell Lung Cancer (NSCLC)

Interventions: Drug: Nivolumab

First Posted Date: 2014-02-19

Last Posted Date: 2022-10-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1428

Registration Number: NCT02066636

Locations: 🇺🇸
Comprehensive Blood And Cancer Center, Bakersfield, California, United States
🇺🇸
Ucla Hema/Onc-Santa Monica, Los Angeles, California, United States
🇺🇸
Central Georgia Cancer Care, Pc, Macon, Georgia, United States

and more 115 locations

A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Phase 1

Completed

Conditions: Hematologic Neoplasms

Interventions: Biological: BMS-986016
Biological: BMS-936558

First Posted Date: 2014-02-13

Last Posted Date: 2023-03-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 106

Registration Number: NCT02061761

Locations: 🇺🇸
Local Institution - 0002, Portland, Oregon, United States
🇺🇸
Local Institution - 0007, Baltimore, Maryland, United States
🇺🇸
Local Institution - 0001, Seattle, Washington, United States

and more 7 locations

A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

Phase 2

Completed

Conditions: Microsatellite Stable Colorectal Cancer
Mismatch Repair Proficient Colorectal Cancer
Microsatellite Unstable Colorectal Cancer
Mismatch Repair Deficient Colorectal Cancer

Interventions: Drug: Ipilimumab
Drug: Nivolumab
Drug: Daratumumab
Drug: BMS-986016
Drug: Cobimetinib

First Posted Date: 2014-02-11

Last Posted Date: 2024-11-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 385

Registration Number: NCT02060188

Locations: 🇺🇸
Local Institution - 0028, Gilbert, Arizona, United States
🇺🇸
Local Institution - 0004, Los Angeles, California, United States
🇺🇸
Local Institution - 0036, Boston, Massachusetts, United States

and more 29 locations

Ipilimumab 12-month Intensive Pharmacovigilance Protocol

Completed

Conditions: Melanoma

Interventions: Drug: Ipilimumab

First Posted Date: 2014-01-31

Last Posted Date: 2015-07-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 6

Registration Number: NCT02050594

Locations: 🇻🇪
Local Institution, Caracas, Venezuela

Drug Interaction & Methadone & Buprenorphine

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: DCV 3DAA FDC
Drug: Methadone
Drug: BMS-791325
Drug: Buprenorphine
Drug: Naloxone

First Posted Date: 2014-01-27

Last Posted Date: 2014-06-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT02045693

Locations: 🇺🇸
Cri Lifetree, Philadelphia, Pennsylvania, United States
🇺🇸
Anaheim Clinical Trials Llc, Anaheim, California, United States
🇺🇸
Lifetree Clinical Research, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy